Inter‐relationships between cardiovascular, renal and metabolic diseases: Underlying evidence and implications for integrated interdisciplinary care and management

Cardiovascular, renal and metabolic (CaReMe) diseases are individually among the leading global causes of death, and each is associated with substantial morbidity and mortality. However, as these conditions commonly coexist in the same patient, the individual risk of mortality and morbidity is further compounded, leading to a considerable healthcare burden. A number of pathophysiological pathways are common to diseases of the CaReMe spectrum, including neurohormonal dysfunction, visceral adiposity and insulin resistance, oxidative stress and systemic inflammation. Because of the shared pathology and common co‐occurrence of the CaReMe diseases, the value of managing these conditions holistically is increasingly being realized. A number of pharmacological and non‐pharmacological approaches have been shown to offer simultaneous metabolic, cardioprotective and renoprotective benefits, leading to improved patient outcomes across the CaReMe spectrum. In addition, increasing value is being placed on interdisciplinary team‐based and coordinated care models built on greater integration between specialties to increase the rate of early diagnosis and adherence to practice guidelines, and improve clinical outcomes. This interdisciplinary approach also facilitates integration between primary and specialty care, improving the patient experience, optimizing resources, and leading to efficiencies and cost savings. As the burden of CaReMe diseases continues to increase, implementation of innovative and integrated care delivery models will be essential to achieve effective and efficient chronic disease management and to ensure that patients benefit from the best care available across all three disciplines.

[1]  S. Bungău Cardio-Renal Metabolic Syndrome: Interdisciplinary Diagnostic Methods , 2023, Diagnostics.

[2]  Eric L. Johnson,et al.  10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2023. , 2022, Diabetes care.

[3]  K. Khunti,et al.  KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. , 2022, Kidney international.

[4]  Connie M. Rhee,et al.  Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO) , 2022, Diabetes care.

[5]  Deepak L. Bhatt,et al.  Comprehensive Management of Cardiovascular Risk Factors for Adults With Type 2 Diabetes: A Scientific Statement From the American Heart Association , 2022, Circulation.

[6]  E. Lerma,et al.  Heart Failure in Patients with Diabetes and Chronic Kidney Disease: Challenges and Opportunities , 2021, Cardiorenal Medicine.

[7]  N. Sattar,et al.  Cardiovascular Outcomes Trials for Weight Loss Interventions: Another Tool for Cardiovascular Prevention? , 2021, Circulation.

[8]  K. Khunti,et al.  Cardiovascular risk factors early in the course of treatment in people with type 2 diabetes without established cardiovascular disease: A population‐based observational retrospective cohort study , 2021, Diabetic medicine : a journal of the British Diabetic Association.

[9]  J. McEvoy,et al.  Aspirin in the Modern Era of Cardiovascular Disease Prevention , 2021, Methodist DeBakey cardiovascular journal.

[10]  I. V. Van Gelder,et al.  2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. , 2021, European heart journal.

[11]  Neha J. Pagidipati,et al.  A comprehensive cardiovascular-renal-metabolic risk reduction approach to patients with Type 2 Diabetes Mellitus. , 2021, The American journal of medicine.

[12]  Chiadi E. Ndumele,et al.  Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association , 2021, Circulation.

[13]  L. Tokgözoğlu,et al.  An updated perspective and pooled analysis of cardiovascular outcome trials of GLP-1 receptor agonists and SGLT-2 inhibitors. , 2021, Anatolian journal of cardiology.

[14]  J. McMurray,et al.  Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial. , 2021, The lancet. Diabetes & endocrinology.

[15]  Sathish Kumar Jayapal,et al.  Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019 , 2020, Journal of the American College of Cardiology.

[16]  F. Giorgino,et al.  Renoprotection with SGLT2 inhibitors in type 2 diabetes over a spectrum of cardiovascular and renal risk , 2020, Cardiovascular Diabetology.

[17]  M. Vaduganathan,et al.  Cardio-Renal-Metabolic Care Models , 2020, Circulation. Cardiovascular quality and outcomes.

[18]  J. McMurray,et al.  Dapagliflozin in Patients with Chronic Kidney Disease. , 2020, The New England journal of medicine.

[19]  P. Ponikowski,et al.  Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure , 2020, New England Journal of Medicine.

[20]  K. Khunti,et al.  Association and relative importance of multiple risk factor control on cardiovascular disease, end-stage renal disease and mortality in people with type 2 diabetes: A population-based retrospective cohort study. , 2020, Primary care diabetes.

[21]  Ilia G. Halatchev,et al.  A patient-centred, comprehensive model for the care for heart failure: the 360° heart failure centre , 2020, Open Heart.

[22]  Pamela Mazzocato,et al.  Time-driven activity-based costing for patients with multiple chronic conditions: a mixed-method study to cost care in a multidisciplinary and integrated care delivery centre at a university-affiliated tertiary teaching hospital in Stockholm, Sweden , 2020, BMJ Open.

[23]  J. O’Keefe,et al.  Abstract 369: Secondary Risk Reduction in Patients With Type 2 Diabetes and Cardiovascular Disease: Experience From a Cardiometabolic Center of Excellence , 2020, Circulation: Cardiovascular Quality and Outcomes.

[24]  M. Vaduganathan,et al.  Training the Next Generation of Cardiometabolic Specialists. , 2020, Journal of the American College of Cardiology.

[25]  Sanjiv J. Shah,et al.  Quality of life in heart failure with preserved ejection fraction: importance of obesity, functional capacity, and physical inactivity , 2020, European journal of heart failure.

[26]  M. Evans,et al.  Renal Outcomes in Type 2 Diabetes: A Review of Cardiovascular and Renal Outcome Trials , 2019, Diabetes Therapy.

[27]  D. Wheeler,et al.  Impact of Cardio-Renal-Metabolic Comorbidities on Cardiovascular Outcomes and Mortality in Type 2 Diabetes Mellitus , 2019, American Journal of Nephrology.

[28]  Pamela Mazzocato,et al.  Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic , 2019, Journal of multidisciplinary healthcare.

[29]  Akshay S. Desai,et al.  Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. , 2019, The New England journal of medicine.

[30]  Deepak L. Bhatt,et al.  Ticagrelor in Patients with Stable Coronary Disease and Diabetes. , 2019, The New England journal of medicine.

[31]  C. Lavie,et al.  Obesity paradox in cardiovascular disease: where do we stand? , 2019, Vascular health and risk management.

[32]  C. Ronco,et al.  Cardiorenal Syndrome: Classification, Pathophysiology, Diagnosis, and Treatment Strategies: A Scientific Statement From the American Heart Association. , 2019, Circulation.

[33]  P. McFarlane,et al.  The role of sodium glucose cotransporter-2 (SGLT-2) inhibitors in heart failure and chronic kidney disease in type 2 diabetes , 2019, Current medical research and opinion.

[34]  J. Spaak,et al.  Health care professionals’ experiences and enactment of person-centered care at a multidisciplinary outpatient specialty clinic , 2019, Journal of multidisciplinary healthcare.

[35]  Deepak L. Bhatt,et al.  Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes , 2019, The New England journal of medicine.

[36]  A. Roddick,et al.  Association of Aspirin Use for Primary Prevention With Cardiovascular Events and Bleeding Events: A Systematic Review and Meta-analysis , 2019, JAMA.

[37]  P. Schauer,et al.  Bariatric Surgery Decreases Mortality of Congestive Heart Failure: A Nationwide Study , 2018, Surgery for Obesity and Related Diseases.

[38]  C. Ronco,et al.  Hepatorenal Syndrome or Hepatocardiorenal Syndrome: Revisiting Basic Concepts in View of Emerging Data , 2018, Cardiorenal Medicine.

[39]  Björn Eliasson,et al.  Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes , 2018, The New England journal of medicine.

[40]  Jackson T. Wright,et al.  2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2018, Journal of the American Society of Hypertension : JASH.

[41]  Sanjiv J. Shah,et al.  The Association of Obesity and Cardiometabolic Traits With Incident HFpEF and HFrEF. , 2018, JACC. Heart failure.

[42]  S. Arnold,et al.  Burden of cardio‐renal‐metabolic conditions in adults with type 2 diabetes within the Diabetes Collaborative Registry , 2018, Diabetes, obesity & metabolism.

[43]  T. Einarson,et al.  Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017 , 2018, Cardiovascular Diabetology.

[44]  K. Khunti,et al.  Legacy benefits of blood glucose, blood pressure and lipid control in individuals with diabetes and cardiovascular disease: Time to overcome multifactorial therapeutic inertia? , 2018, Diabetes, obesity & metabolism.

[45]  J. Shaw,et al.  Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study. , 2018, Journal of the American College of Cardiology.

[46]  P. Damman,et al.  Optimal duration of dual antiplatelet therapy for coronary artery disease , 2018, Netherlands Heart Journal.

[47]  E. Bonora,et al.  Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease: A systematic review and meta-analysis. , 2018, Metabolism: clinical and experimental.

[48]  B. Zinman,et al.  Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial , 2018, European heart journal.

[49]  R. Guthrie Canagliflozin and cardiovascular and renal events in type 2 diabetes , 2018, Postgraduate medicine.

[50]  A. Khorana,et al.  Multidisciplinary Clinics for Colorectal Cancer Care Reduces Treatment Time , 2017, Clinical colorectal cancer.

[51]  J. Metsemakers,et al.  Cardiovascular disease patients have increased risk for comorbidity: A cross-sectional study in the Netherlands , 2017, The European journal of general practice.

[52]  E. Han,et al.  Non-Alcoholic Fatty Liver Disease: The Emerging Burden in Cardiometabolic and Renal Diseases , 2017, Diabetes & metabolism journal.

[53]  Neha J. Pagidipati,et al.  Effects of Once‐Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes , 2017, The New England journal of medicine.

[54]  E. Loza,et al.  Experience and satisfaction with a multidisciplinary care unit for patients with psoriasis an psoriatic arthritis. , 2017, Reumatologia clinica.

[55]  I. D. de Boer,et al.  Diabetes and Hypertension: A Position Statement by the American Diabetes Association , 2017, Diabetes Care.

[56]  M. Farkouh,et al.  Recent Insights into Pharmacologic Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus , 2017, Cardiovascular Drugs and Therapy.

[57]  C. Byrne,et al.  Non-alcoholic fatty liver disease: an emerging driving force in chronic kidney disease , 2017, Nature Reviews Nephrology.

[58]  Massimo F. Piepoli,et al.  2016 European Guidelines on cardiovascular disease prevention in clinical practice , 2017, International Journal of Behavioral Medicine.

[59]  J. Spaak,et al.  Novel Combined Management Approaches to Patients with Diabetes, Chronic Kidney Disease and Cardiovascular Disease , 2017, The journal of the Royal College of Physicians of Edinburgh.

[60]  R. Rivera,et al.  Multidisciplinary Care Models for Patients With Psoriatic Arthritis. , 2017, Reumatologia clinica.

[61]  K. Khunti,et al.  Aspirin for primary prevention of cardiovascular and all‐cause mortality events in diabetes: updated meta‐analysis of randomized controlled trials , 2017, Diabetic medicine : a journal of the British Diabetic Association.

[62]  A. Hoes,et al.  2016 European Guidelines on cardiovascular disease prevention in clinical practice. , 2016, Revista espanola de cardiologia.

[63]  D. Atar,et al.  Neurohormonal Blockade in Heart Failure. , 2016, Cardiac failure review.

[64]  Lawrence A Leiter,et al.  Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. , 2016, The New England journal of medicine.

[65]  J. Radhakrishnan,et al.  Cardio-renal syndrome , 2016, F1000Research.

[66]  O. Pedersen,et al.  Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial , 2016, Diabetologia.

[67]  Deepak L. Bhatt,et al.  Reduction in Ischemic Events With Ticagrelor in Diabetic Patients With Prior Myocardial Infarction in PEGASUS-TIMI 54. , 2016, Journal of the American College of Cardiology.

[68]  J. Buse,et al.  Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. , 2016, The New England journal of medicine.

[69]  P. Grant,et al.  Diabetes and cardiovascular disease: pathophysiology of a life-threatening epidemic , 2016, Herz.

[70]  M. Fischereder,et al.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. , 2016, The New England journal of medicine.

[71]  Merlin C. Thomas,et al.  Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease , 2016, Nature Reviews Nephrology.

[72]  S. Friedman,et al.  Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. , 2015, Gastroenterology.

[73]  K. Rahimi,et al.  Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. , 2015, JAMA.

[74]  Spiros Denaxas,et al.  Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1·9 million people , 2015, The Lancet.

[75]  Bernadette A. Thomas,et al.  Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013 , 2015, The Lancet.

[76]  Braunwald,et al.  Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. , 2014, The New England journal of medicine.

[77]  Shih-Jen Hwang,et al.  Mid-adulthood risk factor profiles for CKD. , 2014, Journal of the American Society of Nephrology : JASN.

[78]  Jennette P. Moreno,et al.  Cardiovascular Effects of Intensive Lifestyle Intervention in Type 2 Diabetes , 2014, Current Atherosclerosis Reports.

[79]  H. Keen,et al.  The concomitants of raised blood sugar: studies in newly-detected hyperglycaemics: II. Urinary albumin excretion, blood pressure and their relation to blood sugar levels. , 2014, International journal of epidemiology.

[80]  F. Mallamaci,et al.  Obesity and CKD progression: hard facts on fat CKD patients. , 2013, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[81]  W. Paulus,et al.  A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. , 2013, Journal of the American College of Cardiology.

[82]  N. Sattar,et al.  Revisiting the links between glycaemia, diabetes and cardiovascular disease , 2013, Diabetologia.

[83]  M. Woodward,et al.  Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis , 2012, The Lancet.

[84]  O. Djurdjev,et al.  Towards rational approaches of health care utilization in complex patients: an exploratory randomized trial comparing a novel combined clinic to multiple specialty clinics in patients with renal disease-cardiovascular disease-diabetes. , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[85]  O. Djurdjev,et al.  The effect of a multidisciplinary care clinic on the outcomes in pediatric chronic kidney disease , 2012, Pediatric Nephrology.

[86]  D. Matthews,et al.  Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach , 2012, Diabetes Care.

[87]  R. Bergenstal,et al.  Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) , 2012, Diabetologia.

[88]  L. Ruilope,et al.  Prevention of microalbuminuria in patients with type 2 diabetes and hypertension , 2012, Journal of hypertension.

[89]  Josef Coresh,et al.  Chronic kidney disease , 2012, The Lancet.

[90]  Patrick J Heagerty,et al.  Temporal trends in the prevalence of diabetic kidney disease in the United States. , 2011, JAMA.

[91]  T. Wadden,et al.  Benefits of Modest Weight Loss in Improving Cardiovascular Risk Factors in Overweight and Obese Individuals With Type 2 Diabetes , 2011, Diabetes Care.

[92]  B. Massie,et al.  Body Mass Index and Adverse Cardiovascular Outcomes in Heart Failure Patients With Preserved Ejection Fraction: Results From the Irbesartan in Heart Failure With Preserved Ejection Fraction (I-PRESERVE) Trial , 2011, Circulation. Heart failure.

[93]  Amitabh Srivastava,et al.  Effect of initiating a multidisciplinary care clinic on access and time to treatment in patients with pancreatic adenocarcinoma. , 2010, Journal of oncology practice.

[94]  R. Cottrell,et al.  A review and meta-analysis of the effect of weight loss on all-cause mortality risk , 2009, Nutrition Research Reviews.

[95]  R. Collins,et al.  Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials , 2009, The Lancet.

[96]  Grant D. Huang,et al.  Glucose control and vascular complications in veterans with type 2 diabetes. , 2009, The New England journal of medicine.

[97]  R. Holman,et al.  10-year follow-up of intensive glucose control in type 2 diabetes. , 2008, The New England journal of medicine.

[98]  R. Bilous,et al.  Microvascular disease: what does the UKPDS tell us about diabetic nephropathy? , 2008, Diabetic medicine : a journal of the British Diabetic Association.

[99]  G. Fonarow,et al.  Body mass index and mortality in heart failure: a meta-analysis. , 2008, American heart journal.

[100]  Diederick Grobbee,et al.  Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. , 2008, The New England journal of medicine.

[101]  R Peto,et al.  Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. , 2008, Lancet.

[102]  H. Parving,et al.  Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective. , 2006, Kidney international.

[103]  Rury R Holman,et al.  Risk Factors for Renal Dysfunction in Type 2 Diabetes , 2006, Diabetes.

[104]  Carlos Iribarren,et al.  Body Mass Index and Risk for End-Stage Renal Disease , 2006, Annals of Internal Medicine.

[105]  A. Levin,et al.  Kidney function and mortality among patients with left ventricular systolic dysfunction. , 2005, Journal of the American Society of Nephrology : JASN.

[106]  R. Collins,et al.  Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA). , 2005, Diabetes care.

[107]  Florian Kronenberg,et al.  Renal insulin resistance syndrome, adiponectin and cardiovascular events in patients with kidney disease: the mild and moderate kidney disease study. , 2005, Journal of the American Society of Nephrology : JASN.

[108]  M. Mauer,et al.  Preventing microalbuminuria in type 2 diabetes. , 2005, The New England journal of medicine.

[109]  John H Fuller,et al.  Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial , 2004, The Lancet.

[110]  Samy I McFarlane,et al.  Diabetes, hypertension, and cardiovascular derangements: Pathophysiology and management , 2004, Current hypertension reports.

[111]  Sarah Parish,et al.  MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial , 2003, The Lancet.

[112]  A. Mattioli,et al.  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.

[113]  R. Peto,et al.  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.

[114]  W. Rand,et al.  Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. , 2001, Journal of the American College of Cardiology.

[115]  J. Coresh,et al.  Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study. , 2000, Kidney international.

[116]  Uk-Prospective-Diabetes-Study-Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) , 1998, The Lancet.

[117]  S. Bianchi,et al.  Hyperinsulinemia, circadian variation of blood pressure and end-organ damage in hypertension. , 1997, Journal of nephrology.

[118]  M. Inaba,et al.  Insulin resistance in non-obese, non-insulin-dependent diabetic patients with diabetic nephropathy. , 1997, Metabolism: clinical and experimental.

[119]  J. Singer,et al.  Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention. , 1996, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[120]  Walker,et al.  Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients , 1994 .

[121]  K. McPherson,et al.  Secondary prevention of vascular disease by prolonged antiplatelet treatment , 1988, British medical journal.

[122]  R. DeFronzo,et al.  Insulin resistance in uremia. , 1981, The Journal of clinical investigation.

[123]  J. Goodall,et al.  Treatment of hypertension. , 1960, The Central African journal of medicine.

[124]  Daxin Wang,et al.  Letter by Wang et al Regarding Article, "Age at Diagnosis of Type 2 Diabetes Mellitus and Associations With Cardiovascular and Mortality Risks". , 2019, Circulation.

[125]  Diabetes Federation IDF Diabetes Atlas 9th Edition , 2019 .

[126]  Diane M. Miller,et al.  Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. , 2018, Lancet.

[127]  K. Koh “ Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs : The CVD-REAL Study ( Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors ) , 2018 .

[128]  H. Parving,et al.  Microalbuminuria: a parameter that has changed diabetes care. , 2015, Diabetes research and clinical practice.

[129]  A. Aplogan,et al.  From the Centers for Disease Control and Prevention , 2015 .

[130]  R. Gansevoort,et al.  Albuminuria Is an Appropriate Therapeutic Target in Patients with CKD: The Pro View. , 2015, Clinical journal of the American Society of Nephrology : CJASN.

[131]  S. Schinner Effects of Intensive Glucose Lowering in Type 2 Diabetes , 2009 .

[132]  Rury R Holman,et al.  Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). , 2003, Kidney international.

[133]  C. Ballantyne Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA) , 2003 .

[134]  Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. , 1994, BMJ.